肝X受体的基因多态性与代谢类疾病的相关性

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (6): 713-720.

• 综述与讲座 • 上一篇

肝X受体的基因多态性与代谢类疾病的相关性

赵慧佳¹，李玲¹，魏婉慧¹，徐千¹，时玉颖¹，乐江³，王彦峰¹，叶啟发^1,2

¹武汉大学中南医院，武汉大学肝胆疾病研究院，武汉大学移植医学中心，移植医学技术湖北省重点实验室，武汉 430071 ，湖北； ²中南大学湘雅三医院，卫生部移植医学工程技术研究中心，长沙 410013，湖南；³武汉大学基础医学院药理教研室，武汉 430071，湖北

收稿日期:2016-11-30 修回日期:2017-02-06 出版日期:2017-06-26 发布日期:2017-06-26
通讯作者: 叶啟发，男，教授，主任医师，研究方向：肝胆外科，器官移植。 Tel: 027-67812988E-mail: yqf-china@163.com
作者简介:赵慧佳，女，本科，研究方向：基因多态性在器官移植中的应用。

Relativity between the gene polymorphisms of LXR and metabolic syndrome

ZHAO Huijia ¹, LI Ling¹, WEI Wanhui ¹, XU Qian ¹, SHI Yuying ¹, YUE Jiang³, WANG yanfeng ¹, Ye Qifa ^1,2

¹Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Transplant Center of Wuhan University, Hubei Key Laboratory of Medical Technology on Transplantation，Wuhan 430071, Hubei, China；²The 3rd Xiangya Hospital of Central South University, Research Center of National Health Ministry on Transplantation Medicine Engineering and Technology, Changsha 410013, Hubei, China; ³ The Department of Pharmacology in the Basic Medical Department of Wuhan University, Wuhan 430071, Hubei, China

Received:2016-11-30 Revised:2017-02-06 Online:2017-06-26 Published:2017-06-26

摘要/Abstract

摘要：

肝X受体（liver X receptor,LXR）是人体内一种重要的核受体，为配体依赖性蛋白。LXR作为体内激素和营养信号的整合者，主要通过调控脂质和糖类等途径调节机体新陈代谢，参与Ⅱ型糖尿病、肥胖、心血管疾病、高脂血症等多种常见代谢疾病的发生发展。有研究证明，多个LXR基因多态性位点与代谢类疾病发生发展密切相关。研究LXR参与代谢性疾病的病理机制、探究LXR基因多态性与代谢性疾病的相关性,有利于从基因层面检测和评估代谢类疾病的发生风险，从而实现早期发现和预防该疾病的发生，提高代谢性疾病患者的生存质量，延长生存期。本文拟就近五年LXR参与代谢途径和其基因多态性与代谢性疾病的相关性做一综述。

关键词: 肝X受体, 代谢性疾病, 基因多态性

Abstract:

Liver X receptor(LXR) is an important nuclear receptor in the body, which is a ligand-dependent protein. LXR is an integrator of hormonal and nutritional signal mediating changes to metabolic pathways of lipid and glucose within the body. It's involved in various common metabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, hyperlipidaemia, and so on. Some studies proved that a number of gene polymorphism sites in LXR were linked with metabolic diseases. Studying the pathological mechanism of LXR in metabolic diseases and researching the correlation between gene polymorphism of LXR and metabolic diseases are beneficial to detecting and assessing the risks of metabolic diseases genetically, which can discover and prevent the diseases early so as to improve the quality of life of patients and prolong living time. This review focuses on the metabolism of LXR and the correlation between the gene polymorphism and metabolic diseases of LXR.

Key words: liver X receptor, metabolic diseases, gene polymorphism

中图分类号:

R968

赵慧佳，李玲，魏婉慧，徐千，时玉颖，乐江，王彦峰，叶啟发. 肝X受体的基因多态性与代谢类疾病的相关性[J]. 中国临床药理学与治疗学, 2017, 22(6): 713-720.

ZHAO Huijia, LI Ling, WEI Wanhui, XU Qian, SHI Yuying, YUE Jiang, WANG yanfeng, Ye Qifa. Relativity between the gene polymorphisms of LXR and metabolic syndrome[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 713-720.

参考文献

［1］RankinenT , Sarzynski MA , Ghosh S, et al. Are There genetic paths common to obesity, cardiovascular disease outcomes, and cardiov- ascular risk factors［J］?Circ Res, 2015, 116(5): 909-922.
［2］Bi XK,Song JL,Gao J, et al. Activation of liver X receptor attenuates lysophosphatidylcholine-induced IL-8 expression in endothelial cells via the NF-κB pathway and SUMOylation［J］. J Cell Mol Med, 2016, 20(10): 1-10.
［3］Zhang L, Chen YL, Yang XX, et al. MEK1/2 inhibitors activate macrophage ABCG1 expression and reverse cholesterol transport-An anti-atherogenic function of ERK1/2 inhibition［J］. Biochimica et Biophysica Acta, 2016, (1861): 1180-1191.
［4］Kiss M, Czimmerer Z, Nagy L,et al. The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology［J］. J Allergy Clin Immunol， 2013, 132(2): 264-286.
［5］Huwait EA, Singh NN, Michael DR. Protein kinase C is involved in the induction of ATP-binding cassette transporter A1 expression by liver X receptor /retinoid X receptor agonist in human macrophages［J］.J Cell Biochem， 2015, 116(9): 2032-2038.
［6］Nagy L, Szanto A, Szatmari I, et al. Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response［J］. Physiol Rev, 2012, 92(2): 739-789.
［7］Venkateswaran A, Laffitte BA, Joseph SB,et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα［J］. Proc Natl Acad Sci USA,2000,97(22)：12097-12102.
［8］Hong YF, Kim H, Kim HS. Lactobacillus acidophilus K301 Inhibits Atherogenesis via Induction of 24 (S), 25- Epoxycholesterol-Mediated ABCA1 and ABCG1 Production and Cholesterol Efflux in Macrophages［J］. PLoS One, 2016, 11(4): 1-18.
［9］Fang L, Choi SH, Baek JS, Liu C. Control of Angiogenesis by AIBP-mediated Cholesterol Efflux［J］. Nature, 2013, 498(7452): 118-122.
［10］Hong C, Walczak R, Dhamko H, et al. Constitutive activation of LXR in macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target［J］. J Lipid Res，2011，52(3):531-539.
［11］Kirchgessner TG,Sleph P, Ostrowski J,et al. Beneficial and adverse effects of an lxr agonist on human lipid and lipoprotein metabolism and circulating neutrophils［J］.Cell Metabolism, 2016,24(2):223-233.
［12］Peet DJ, Turley SD, Ma W, et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα［J］. Cell，1998，93(5):693-704.
［13］Hsieh J, Koseki M, Molusky MM, et al. TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis［J］.Nature, 2016, 535(7611): 303-307.
［14］Hgmoen strand OA,Gikling I, Sylte I,et al. Development of new LXR modulators that regulate LXR target genes and reduce lipogenesis in human cell models［J］. Eur J Med Chem, 2014, 74: 258-263.
［15］Kawase A, Hata S, Takagi M, et al. Pravastatin modulate niemann-pick c1-like 1 and atp-binding cassette g5 and g8 to influence intestinal cholesterol absorption［J］. J Pharm Pharm Sci, 2015, 18(5): 765-772.
［16］van der Veen JN, van Dijk TH, Vrins CL，et al. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol［J］.J Biol Chem，2009，284(29):19211-19219.
［17］Kartawijaya M, Han HW, Kim Y，et al. Genistein upregulates LDLR levels via JNK-mediated activation of SREBP-2［J］. Food Nutr Res, 2016, 60(31120): 302-309.
［18］Guo D, Reinitz F, Youssef F, et al. An LXR agonist promotes GBM cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR -dependent pathway［J］. Cancer Discov, 2011, 1(5): 442-456.
［19］Shavva VS, Bogomolova AM, Nikitin AA,et al. Insulin-Mediated Downregulation of Apolipoprotein A-I Gene in Human Hepatoma Cell Line HepG2: The Role of Interaction between FOXO1 and LXRβ Transcription Factors［J］. J Cell Biochem, 2016,doi: 10.1002/jcb.25651.
［20］Mitro N, Mak PA, Vargas L，et al.The nuclear receptor LXR is a glucose sensor［J］. Nature，2007, 445(7124):219-223.
［21］Pettersson AM, Stenson BM, Lorente-Cebrián S，et al.LXR is a negative regulator of glucose uptake in human adipocytes［J］. Diabetologia, 2013, 56(9): 2044-2054.
［22］Korach-André M, Archer A, Barros RP, et al. Both liver-X receptor (LXR) isoforms control energy expenditure by regulating brown adipose tissue activity［J］. Proc Natl Acad Sci USA, 2011, 108(1): 403-408.
［23］Stenson BM, Rydén M, Steffensen KR, et al. Activation of liver X receptor regulates substrate oxidation in white adipocytes［J］. Endocrinology，2009，150(9):4104-4113.
［24］Ketterer C, Müssig K,Machicao F,et al. Genetic variation within the NR1H2 gene encoding liver X receptor β associates with insulin secretion in subjects at increased risk for type 2 diabetes［J］. J Mol Med, 2011, (89): 75-81.
［25］Solaas K, Legry V, Retterstol K, et al. Suggestive evidence of associations between liver X receptor b polymorphisms with type 2 diabetes mellitus and obesity in three cohort studies: HUNT2 (Norway), MONICA (France) and HELENA (Europe)［J］. BMC Medical Genetics, 2010, 11(144): 234-244.
［26］Sharma KL, Misra S, Kumar A,et al. Association of liver X receptors (LXRs) genetic variants to gallbladder cancer susceptibility［J］. Tumour Biol, 2013, 34(6): 3959-3966.
［27］Stender S, Frikke-Schmidt R, Anestis A,et al. Genetic Variation in Liver X Receptor Alpha and Risk of Ischemic Vascular Disease in the General Population［J］. Arterioscler Thromb Vasc Biol, 2011, (31): 2990-2996.
［28］Yang JS, Hao JJ, Wang SS,et al. Association between the LXRα polymorphism and stroke in a Chinese population［J］. Genet Mol Res, 2015, 14(1): 1757-1762.
［29］Han M, Liang L, Liu LR, et al. Liver X Receptor Gene Polymorphisms in Tuberculosis: Effect on Susceptibility［J］. PLoS ONE,2014,9(5):e95954. doi:10.1371/journal.pone.0095954.
［30］Legry V, Bokor S, Beghin L,et al. Associations between common genetic polymorphisms in the liver X receptor alpha and its target genes with the serum HDL-cholesterol concentration in adolescents of the HELENA Study［J］. Atherosclerosis, 2011, (216): 166-169.
［31］Price ET, Pacanowski MA, Martin MA,et al. Liver X receptorα gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy results from the INVEST-GENES study［J］. Pharmacogenet Genomics, 2011, 21(6): 333-340.
［32］Zhou YF, Zhang J, Li ZX, et al. Association of liver X receptor α (LXRα) gene polymorphism and coronary heart disease, serum lipids and glucose levels［J］. Lipids Health Dis, 2014, 13(34): 25-29.
［33］Adighibe O, Arepalli S, Duckworth J,et al. Genetic variability at the LXR gene (NR1H2) may contribute to the risk of Alzheimer's disease［J］. Neurobiol Aging，2006, 27(10): 1431-1434.
［34］Infante J, Rodríguez-Rodríguez E, Mateo I,et al. Gene-gene interaction between heme oxygenase-1 and liver X receptor- and Alzheimer's disease risk［J］.Neurobiol Aging，2010, 31(4)：710-714.
［35］Natunen T, Martiskainen H, Sarajrvi T,et al.Effects of NR1H3 genetic variation on the expression of liver x receptor a and the progression of Alzheimer's disease［J］.PLoS One, 2013, 8(11): e80700.
［36］汪江林，左笑丛，杨梦等. 钙调神经磷酸酶/NFATc信号通路介导他克莫司诱导移植后糖尿病的研究进展［J］. 中国临床药理学与治疗学，2014,19（1）：74-80.
［37］Sabine G , Maximilian J, Maciej M,et al. Risk factors of metabolic disorders after liver transplantation: an analysis of data from fasted patient.［J］. Transplantation, 2015, 99(6): 1243-1249.
［38］Chang AL, Cortez AR，Bondoc A,et al. Metabolic syndrome in liver transplantation: A preoperative and postoperative concern［J］. Surgery, 2016,160(4):1111-1117.
［39］Kiss E, Popovic Z, Bedke J,et al.Suppression of chronic damage in renal allografts byLiver X receptor (LXR) activation relevant contributionof macrophage LXRα［J］. Am J Pathol , 2011, 179(1): 92-103.
［40］Wang Y, Li C, Cheng K,et al. Activation of Liver X Receptor Improves Viability of Adipose-Derived Mesenchymal Stem Cells to Attenuate Myocardial Ischemia Injury Through TLR4/NF-jB and Keap-1/Nrf-2 Signaling Pathways［J］. Antioxid Redox Signal，2014, 21(18): 2543-2557.
［41］Bhargava M, Viken KJ, Dey S,et al. Proteome profiling in lung injury after hematopoietic stem cell transplantation［J］.Biol Blood Marrow Transplant，2016，22(8): 1383-1390.
［42］Ergen HA, Zeybek U, Gok O,et al. Investigation of ABCA1 C69T polymorphism in patients with type 2 diabetes mellitus［J］. Biochem Med (Zagreb) , 2012, 22(1): 114-120.
［43］Kalantarian S, Rimm EB, Herrington DM,et al. Dietary macronutrients, genetic variation, and progression of coronary atherosclerosis among women［J］. Am Heart J, 2014, 167(4): 627-635.

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[3]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[4]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[5]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[6]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[7]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[8]	武元竹, 刘俊, 杨魁, 彭静, 栾家杰, 韦俊, 张大发, 宋帅, 袁小龙, 王中方, 张年宝, 解丹, 姜鹏, 范洁. 安徽地区汉族人群CYP2C9*3和VKORC1-1639G>A基因多态性分布及对华法林稳定剂量的影响[J]. 中国临床药理学与治疗学, 2022, 27(6): 652-659.
[9]	陈佳音, 王丽, 王立军, 童刚领, 马洁, 陈西敬, 卢杨. 有机阳离子转运体基因多态性与奥沙利铂毒性及疗效的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(2): 171-177.
[10]	周敏敏, 余露, 韩超, 顾达民, 雷道赟. 人类胆固醇酯转移蛋白rs5882基因多态性与围术期神经认知功能紊乱的相关性[J]. 中国临床药理学与治疗学, 2021, 26(7): 768-774.
[11]	王春玲, 周仁精, 冯瑞, 吴燕能. 脂联素45 T/G基因多态性对利拉鲁肽治疗2型糖尿病患者的临床疗效[J]. 中国临床药理学与治疗学, 2021, 26(3): 312-317.
[12]	李静, 马丽娟, 袁圆, 王捷, 郁长治, 赵军. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258.
[13]	杨春艳, 张文, 王培培, 彭静, 江佳, 宋静, 刘俊, 李越然, 杨魁, 汪盛, 徐振宇, 栾家杰. 叶酸代谢通路相关基因多态性对血清同型半胱氨酸浓度的影响[J]. 中国临床药理学与治疗学, 2021, 26(11): 1259-1264.
[14]	梅笛, 沈纪中, 刘春妍, 陆程灿, 徐伟, 彭宇竹. 新型口服抗凝药的药物基因组学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(10): 1200-1207.
[15]	王凤玲, 孟祥云, 陈正徐, 曹荣娟, 何争民, 叶茜, 王聪, 李琪. 安徽地区汉族心血管疾病患者SLCO1B1与ApoE基因多态性分布及其在他汀类药物临床个体化应用中的意义[J]. 中国临床药理学与治疗学, 2021, 26(1): 40-48.

肝X受体的基因多态性与代谢类疾病的相关性

Relativity between the gene polymorphisms of LXR and metabolic syndrome

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价